Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study To Evaluate Long Term Treatment Effect Of Diapep277® In Patients Who Have Completed Study 901 And Study 910** (Extension To 901)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2011 by Hadassah Medical Organization.
Recruitment status was  Not yet recruiting
Information provided by:
Hadassah Medical Organization Identifier:
First received: January 20, 2011
Last updated: NA
Last verified: January 2011
History: No changes posted
Open label study to evaluate long term treatment effect of diapep277.

Condition Intervention Phase
Giving a Vaccination in Three Months
Other: vaccine
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • c peptide reserve


Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Genders Eligible for Study:   Both

Inclusion Criteria:

1. patient that completed 901 and 910 study.

Exclusion Criteria:

1. cpeptide<0.2

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: PROP ITAMAR RAZ, HADASSAH MEDICAL CENTER Identifier: NCT01281072     History of Changes
Other Study ID Numbers: 911-DIAPEP277 
Study First Received: January 20, 2011
Last Updated: January 20, 2011
Health Authority: Israel: Ministry of Health processed this record on October 25, 2016